Expertise in
18
conditions

Dr. Jennifer L. Heaberlin

Oncology
A Hospital Department Of AdventHealth Hendersonville
49 Spicewood Dr Ste 10B, 
Clyde, NC 
Accepting New Patients
18 Years of Experience
Expertise in
18
conditions
A Hospital Department Of AdventHealth Hendersonville
49 Spicewood Dr Ste 10B, 
Clyde, NC 

Overview

Jennifer Heaberlin is an Oncologist practicing medicine in Clyde, North Carolina. She has been practicing medicine for over 18 years.

Dr. Heaberlin is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Urothelial Cancer, Astrocytoma, and Muscle Invasive Bladder Cancer.

She is actively involved in clinical research, participating in 11 clinical trials. Dr. Heaberlin is currently accepting new patients.

Graduate Year

2008

Specialties

Oncology

Licenses

Internal Medicine in NC

Hospital Affiliations

Adventhealth Hendersonville
Harris Regional Hospital
Memorial Mission Hospital And Asheville Surgery Ce
Angel Medical Center
Haywood Regional Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

A hospital department of AdventHealth Hendersonville
49 Spicewood Dr Ste 10B, Clyde, NC 28721

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: May 29, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2026
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Behavioral
Study Phase: Phase 3
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other, Drug
Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
View 9 Less Clinical Trials
Similar Doctors
Expertise in
26
conditions
Dr. Haydar A. Frangoul
Hematology | Oncology
Expertise in
26
conditions
Dr. Haydar A. Frangoul
Hematology | Oncology
Referral may be required

TriStar Medical Group Children's Specialists - West Clinch Ave

2018 Clinch Ave, 
Knoxville, TN 
 (58.5 miles away)
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Haydar Frangoul is a Hematologist and an Oncologist practicing medicine in Knoxville, Tennessee. Dr. Frangoul is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Beta Thalassemia, Congenital Hemolytic Anemia, Hemoglobinopathy, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Frangoul is currently accepting new patients.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Hope Women's Cancer Center

100 Ridgefield Ct, 
Asheville, NC 
 (22.3 miles away)
828-670-8403
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Timothy Vanderkwaak is an Oncologist practicing medicine in Asheville, North Carolina. Dr. Vanderkwaak is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Malignant Mixed Mullerian Tumor, Ovarian Cancer, Virilizing Ovarian Tumor, Hernia Surgery, and Splenectomy. Dr. Vanderkwaak is currently accepting new patients.

Expertise in
12
conditions
Dr. Kim E. Nichols
Hematology | Oncology
Expertise in
12
conditions
Dr. Kim E. Nichols
Hematology | Oncology
Referral may be required
Before you request

ETSU Pediatrics- St. Jude's Clinic

400 N State Of Franklin Rd, Fl 1, 
Johnson City, TN 
 (54.8 miles away)
423-431-3950
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Kim Nichols is a Hematologist and an Oncologist practicing medicine in Johnson City, Tennessee. Dr. Nichols is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Hemophagocytic Lymphohistiocytosis, Non-Langerhans-Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, and Bone Marrow Transplant. Dr. Nichols is board certified in American Board Of Pediatrics. Dr. Nichols is currently accepting new patients.

Frequently Asked Questions about Dr. Jennifer L. Heaberlin

How do I make an appointment with Dr. Jennifer L. Heaberlin?

You can book an appointment with Dr. Jennifer L. Heaberlin by calling their office at 828-209-8459. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jennifer L. Heaberlin a top-rated expert for Paget Disease of the Breast?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jennifer L. Heaberlin is classified as an Distinguished expert for Paget Disease of the Breast, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jennifer L. Heaberlin specialize in?

While Dr. Jennifer L. Heaberlin is a Oncology, they have specific expertise in Paget Disease of the Breast, Urothelial Cancer, and Astrocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jennifer L. Heaberlin accept my insurance?

Dr. Jennifer L. Heaberlin accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 828-209-8459 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Heaberlin's expertise for a condition
ConditionClose
    View All 17 Advanced Conditions
    View All 80 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile